Literature DB >> 10406057

Radiobiological characterization of two human chemotherapy-resistant intermediate grade non-Hodgkin's lymphoma cell lines.

A Aref1, R Mohammad, M Yudelev, R Choudhuri, A Strowbridge, C Orton, A al-Katib.   

Abstract

Intermediate grade non-Hodgkin's lymphoma (IGNHL) is generally considered a radiosensitive tumor that can be controlled with moderate radiation doses. Cell-survival curves of cell lines derived from IGNHL have been typically described to exhibit small or no shoulder, implying inability to accumulate or repair sublethal radiation damage. We characterize in this report the clonogenic radiation survival curves of two human IGNHL cell lines, WSU-DLCL2 and SK-DHL2B, established from patients who expired after having exhibited chemotherapy resistance of their tumors. The cells were irradiated with 60Co radiation at a dose rate of 85-100 cGy/min and cell survival data were analyzed according to the linear quadratic model. The alpha/beta values for WSU-DLCL2 and SK-DHL2B cells are 2 and 8.6, respectively. The corresponding SF2 are 0.42 and 0.35, respectively. Both cell lines are able to repair radiation-induced sublethal damage. These data indicate that these cells are only moderately radiosensitive.

Entities:  

Mesh:

Year:  1999        PMID: 10406057     DOI: 10.1002/(SICI)1520-6823(1999)7:3<158::AID-ROI4>3.0.CO;2-B

Source DB:  PubMed          Journal:  Radiat Oncol Investig        ISSN: 1065-7541


  2 in total

1.  Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy.

Authors:  Robert F Hobbs; Sébastien Baechler; Richard L Wahl; Bin He; Hong Song; Caroline E Esaias; Eric C Frey; Heather Jacene; George Sgouros
Journal:  J Nucl Med       Date:  2010-02-11       Impact factor: 10.057

2.  Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-Hodgkin lymphoma.

Authors:  Robert F Hobbs; Richard L Wahl; Eric C Frey; Yvette Kasamon; Hong Song; Peng Huang; Richard J Jones; George Sgouros
Journal:  J Nucl Med       Date:  2013-08-05       Impact factor: 10.057

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.